Reporting Avenues for Concerns Related to Integrity or Fairness

The Developmental Therapeutics (DT) Study Section reviews applications addressing the experimental therapy of neoplastic diseases (including solid tumors and leukemias) in in vitro systems and in vivo model systems, including some early-stage, pilot clinical trials. The major emphasis of this study section is on the rational development of novel therapeutic strategies that have a significant potential for early translation to the clinic.

The List of Reviewers lists all present, whether standing members or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.

Review Dates

Membership Panel

The membership panel is a list of chartered members only.

Topics


  • Evaluation of drug-delivery strategies (including nanoparticles, liposomes and other delivery vehicles) and gene therapy approaches involving non-immunologic targets for the treatment of cancer.
  • Translational studies of novel antineoplastic agents and pre-clinical drug toxicity, pharmacokinetic/pharmacodynamic and biomarker studies of anticancer agents.
  • Development of anti-angiogenic therapeutic strategies and rational combinations of cytotoxic drugs with novel agents including those targeting: growth factors, signaling, cell cycle regulation, angiogenic, and differentiation pathways.
  • Development and application of mathematical and computational methods for the investigation of combination chemotherapy using small molecules and other modalities.
  • Therapeutic approaches involving biologic response modifiers either alone or in combination with novel or conventional drugs for cancer treatment.
  • Early-stage, pilot clinical trials of novel anticancer therapeutic and drug-delivery strategies involving pharmacokinetic, pharmacodynamic, toxicologic, or pharmacogenomic endpoints.

Shared Interests and Overlaps

There are shared interests with Nanotechnology (NANO) and Bioengineering, Technology, and Surgical Sciences (BTSS) in the areas of nanotechnology related to gene and drug delivery and nanodevices. Applications which focus on the design, synthesis, and development of nanostructures, nanodevices, and nanosystems that could serve as a platform technology for various biological/biomedical applications are appropriate for NANO. Applications which focus on these areas in the context of cancer therapy, are typically assigned to DT while those focused on the surgical setting are typically assigned to BTSS.

There are shared interests with Modeling and Analysis of Biological Systems (MABS) in the areas of mathematical and computer modelling. Applications which focus on the early development of the modeling are appropriate for MABS. Applications which seek to apply the modeling for investigation of combination chemotherapy using small molecules and other modalities for cancer therapy are typically assigned to DT.

There are shared interests with Gene and Drug Delivery Systems (GDD) in the areas of drug and gene delivery devices and vehicles as well as electroporation. Applications which focus on the early development and delivery of drugs, genes, and gene products that could serve as a platform technology for various biological/biomedical applications are appropriate for GDD. Applications that are further in development and focused on cancer therapy are typically assigned to DT.

There are shared interests with Translational Immuno-oncology (TIO) in the areas of oncolytic virotherapy and chemoimmunotherapy. Applications that focus on the immunological aspects of virotherapy may be reviewed in TIO. Applications that are more focused on the non-immunological aspects such as gene therapy may be reviewed in DT. 

There are shared interests with Radiation Therapeutics and Biology (RTB) in the areas of chemo and radiation therapy. Applications which focus on the radiotherapy aspects are appropriate for RTB while applications more focused on the chemotherapy aspects and utilize standard radiation therapy protocols are typically assigned to DT.

There are shared interests with Drug Discovery and Molecular Pharmacology (DMP) in the area of drug development. Applications focused on drug discovery and early drug development are appropriate for DMP while applications involving further development of lead compounds, etc. are typically assigned to DT.

There are shared interests with Clinical Oncology (CONC) in early-stage, pilot clinical trials. Applications that focus on clinical trials with targeted therapy of small molecular inhibitors may be reviewed in CONC. Applications that focus on the experimental therapy of neoplastic diseases in in vitro systems and in vivo model systems, including some pilot clinical trials may be reviewed in DT. 

There are shared interests with Mechanisms of Cancer Therapeutics-A (MCTA) in the therapeutic evaluation of the anti-cancer drug effect. Applications that focus on the mechanism of action of novel anticancer agents and the impact of drug properties on anti-cancer drug function may be reviewed in MCTA. Applications that focus on the pre-clinical development and evaluation of anti-cancer therapeutic and rational combinations of cytotoxic drugs with novel agents may be reviewed in DT. 

There are shared interests with Mechanisms of Cancer Therapeutics-B (MCTB) on therapeutic strategies involving combinations of cytotoxic drugs with targeting agents. Applications that focus on mechanism of action of combination therapies and the effects of drug combination on key oncogenic signaling processes may be reviewed in MCTB. Applications that focus on advanced animal experiments and pilot clinical trials may be reviewed in DT. 

There are shared interests with Mechanisms of Cancer Therapeutics-C (MCTC) on therapeutic strategies involving combinations of cytotoxic drugs with targeting agents. Applications that focus on mechanism of action of novel therapeutic combination strategies that include efficacy studies may be reviewed in MCTC. Applications that focus on advanced animal experiments and pilot clinical trials may be reviewed in DT. 

There are shared interests with Molecular Cancer Diagnosis and Combination (MCDC) in drug efficacies and toxicities. Applications that focus on the development of markers of responses and toxicity of established therapeutic agents may be reviewed in MCDC. Applications that focus on translational studies of novel/established antineoplastic agents and pre-clinical drug toxicity, pharmacokinetic/pharmacodynamic studies of anticancer agents may be reviewed in DT. 

There are shared interests with Clinical Neuroimmunology and Brain Tumors (CNBT) . Therapeutic studies of novel antineoplastic agents and pre-clinical drug toxicity for central nervous system tumors (glioma, medulloblastoma, etc.) may be assigned to DT. Applications involving central nervous system disorders where the focus is on immune response, inflammation and infections should be assigned to CNBT. ​